Комплексний підхід до терапії та профілактики рецидивів бактеріального вагінозу у жінок репродуктивного віку з надмірною масою тіла та ожирінням
DOI:
https://doi.org/10.15574/HW.2020.151-152.89Ключові слова:
бактеріальний вагіноз, надмірна маса тіла, ожиріння, терапія, ремісіяАнотація
Целью исследования была оценка клинической эффективности применения комплексного подхода к терапии и профилактике рецидивов бактериального вагиноза у женщин репродуктивного возраста с избыточной массой тела и ожирением. Обследовано 60 женщин репродуктивного возраста (19–39 лет) с избыточной массой тела и ожирением (ИМТ+30±4,2) и верифицированным диагнозом рецидивирующего бактериального вагиноза (диагностическая система Фемофлор–16).
Эффективность терапии бактериального вагиноза у женщин с избыточной массой тела и ожирением составила 94,0% за счет быстрой элиминации патогенного возбудителя путем применения однократного приема 2 г препарата группы 5-нитроимидазолов Секнидокс и макролидного 16-членного антибиотика с бактерицидным механизмом действия Дорамицин (World Medicine, Великобритания). Комбинированная пролонгированная терапия мультиштаммовым пробиотиком Бревелак и натуральным препаратом Рейтоил способствовала увеличению периода ремиссии бактериального вагиноза до 6 мес в 91,0% пациенток данного контингента.
Посилання
Qin J et al. 2010. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 464;7285:59-65. https://doi.org/10.1038/nature08821; PMid:20203603 PMCid:PMC3779803
Lloyd-Price J, Mahurkar A, Rahnavard G. 2017. Strains, functions and dynamics in the expanded Human Microbiome Project. Nature. 550(7674):61-6. https://doi.org/10.1038/nature23889; PMid:28953883 PMCid:PMC5831082
Stoma IO, Yushchuk ND. 2019. Human microbiome at the junction of Infectology and other branches of medicine: the current state of the problem and reassessment of views on the pathogenesis of diseases. Infektsionnye bolezni: novosti, mneniya, obuchenie. Infectious Diseases: News, Opinions, Training 8(3):78-84.
Tamburini S, Shen N, Wu HC, Clemente JC. 2016. The microbiome in early life: implications for health outcomes. Nat Med. 22(7):713-22. https://doi.org/10.1038/nm.4142; PMid:27387886
Magnúsdóttir S, Thiele I. 2018. Modeling metabolism of the human gut microbiome. Curr. Opin. Biotech. 51:90-6. https://doi.org/10.1016/j.copbio.2017.12.005; PMid:29258014
Yankovskiy DS. 2011. Integralnaya rol simbioticheskoy mikrofloryi v fiziologii cheloveka. K, TOV «Chervona Ruta-Turs»:169.
Aggarwala V, Liang G, Bushman FD. 2017. Viral communities of the human gut: metagenomic analysis of composition and dynamics. Mobile DNA. 8(October):12. https://doi.org/10.1186/s13100-017-0095-y; PMid:29026445 PMCid:PMC5627405
Vieira S, Hiltensperger M, Kumar V. 2018. Translocation of a gut pathobiont drives autoimmunity in mice and humans. Science. 359(6380):1156-61. https://doi.org/10.1126/science.aar7201; PMid:29590047 PMCid:PMC5959731
Rita T. BROOKHEART, Warren G. LEWIS, Association between obesity and bacterial vaginosis as assessed by Nugent score Am J Obstet Gynecol. 2020, May 18.
Sujatha Srinivasan, Martin T Morgan, Tina L. 2015, Mar-Apr. Metabolic Signatures of Bacterial Vaginosis mBio. 6(2). https://doi.org/10.1128/mBio.00204-15; PMid:25873373 PMCid:PMC4453549
Duranti S, Ferrario C, van Sinderen D, Ventura M, Turroni F. 2017. Obesity and microbiota: An example of an intricate relationship. Genes Nutr. 12:18. https://doi.org/10.1186/s12263-017-0566-2; PMid:28638490 PMCid:PMC5473000
Bespalova ID, Ryazantseva NV, Kalyuzhin VV i dr. 2013. Sistemnoe vospalenie v patogeneze metabolicheskogo sindroma i assotsiirovannyih s nim zabolevaniy. Sib. med. zhurn. 2:5-9.
Ma B, Forney LJ, Ravel J. 2012. The vaginal microbiome: rethinking health and diseases. Ann Rev Microbiol. 66:371-389. https://doi.org/10.1146/annurev-micro-092611-150157; PMid:22746335 PMCid:PMC3780402
Andrew B Onderdonk, Mary L Delaney, Raina N Fichorova. 2016, Apr. The Human Microbiome during Bacterial Vaginosis Clin Microbiol Rev. 29(2):223-238. https://doi.org/10.1128/CMR.00075-15; PMid:26864580 PMCid:PMC4786887
Donders GG, Bosmans E, Dekeersmaecker A. 2000. Pathogenesis of abnormal vaginal bacterial flora. Am. J. Obstet. Gynecol. 182:872-878. https://doi.org/10.1016/S0002-9378(00)70338-3
Greenblum S, Turnbaugh PJ, Borenstein E. 2012. Metagenomic systems biology of the human gut microbiome reveals topological shifts associated with obesity and inflammatory bowel disease. Proc. Natl. Acad. Sci. USA. 109:594-599. https://doi.org/10.1073/pnas.1116053109; PMid:22184244 PMCid:PMC3258644
Bartelt A, Heeren J. 2014. Adipose tissue browning and metabolic health. Nat Rev Endocrinol 10:24-36. https://doi.org/10.1038/nrendo.2013.204; PMid:24146030
Kusminski CM, Bickel PE, Scherer PE. 2016. Targeting adipose tissue in the treatment of obesity-associated diabetes. Nat. Rev. Drug Discov. 15:639-660. https://doi.org/10.1038/nrd.2016.75; PMid:27256476
Scherer PE. 2006. Adipose tissue: From lipid storage compartment to endocrine organ. Diabetes. 55:1537-1545. https://doi.org/10.2337/db06-0263; PMid:16731815
Sabrina Duranti, Chiara Ferrario, Douwe van Sinderen. 2017. Obesity and microbiota: an example of an intricate relationship Genes Nutr. 12. https://doi.org/10.1186/s12263-017-0566-2; PMid:28638490 PMCid:PMC5473000
Mitchell C, Marrazzo J. 2014. Bacterial vaginosis and the cervicovaginal immune response. Am J Reprod Immunol. 71(6):555-563. https://doi.org/10.1111/aji.12264; PMid:24832618 PMCid:PMC4128638
Mitchell C, Marrazzo J. 2014. Bacterial vaginosis and the cervicovaginal immune response. Am J Reprod Immunol. 71(6):555-563. https://doi.org/10.1111/aji.12264; PMid:24832618 PMCid:PMC4128638
Fredricks DN, Fiedler TL, Marrazzo JM. 2005. Molecular identification of bacteria associated with bacterial vaginosis. N. Engl. J. Med. 353:1899-1911. https://doi.org/10.1056/NEJMoa043802; PMid:16267321
Beigi RH, Wiesenfeld HC, Hillier SL, Straw T, Krohn MA. 2005. Factors associated with absence of H2O2-producing Lactobacillus among women with bacterial vaginosis. J. Infect. Dis. 191:924-929. https://doi.org/10.1086/428288; PMid:15717268
Genc MR, Vardhana S, Delaney ML, Witkin SS, Onderdonk AB. 2007. TNFA-308G>A polymorphism influences the TNF-alpha response to altered vaginal flora. Eur J Obstet Gynecol Reprod Biol. 134(2):188-191. https://doi.org/10.1016/j.ejogrb.2006.10.018; PMid:17123692
Gianluca Quaranta, Maurizio Sanguinetti, Luca Masucci. 2019. Fecal Microbiota Transplantation: A Potential Tool for Treatment of Human Female Reproductive Tract Diseases Front Immunol. 10: 2653. https://doi.org/10.3389/fimmu.2019.02653; PMid:31827467 PMCid:PMC6890827
Burton JP, Cadieux PA, Reid G. 2003. Improved understanding of the bacterial vaginal microbiota of women before and after probiotic instillation. Appl. Environ. Microbiol. 69:97-101. https://doi.org/10.1128/AEM.69.1.97-101.2003; PMid:12513982 PMCid:PMC152440
Kondratiuk KO, Bodnar PM, Yankovskyi DS. 2015. Likuvannia porushen mikroekolohii kyshechnyka u khvorykh tsukrovym diabetom 2 typu ta nealkoholnoiu zhyrovoiu khvoroboiu pechinky. Gepatologiia 1:42-51.
Russo R, Edu A, De Seta F. 2018. Study on the effects of an oral lactobacilli and lactoferrin complex in women with intermediate vaginal microbiota. Arch Gynecol Obstet. 298(1):139-145. https://doi.org/10.1007/s00404-018-4771-z; PMid:29637269
Ziyue Wang, Yining He, Yingjie Zheng. 2019, Oct. Probiotics for the Treatment of Bacterial Vaginosis: A Meta-Analysis Int J Environ Res Public Health 16(20). https://doi.org/10.3390/ijerph16203859; PMid:31614736 PMCid:PMC6848925
Muzny CA, Schwebke JR. 2016. Pathogenesis of bacterial vaginosis: discussion of current hypotheses. J Infect Dis. 214 (Suppl 1): S1-S5. https://doi.org/10.1093/infdis/jiw121; PMid:27449868 PMCid:PMC4957507
Catriona S Bradshaw, Jack D Sobel. 2016, Aug 15. Current Treatment of Bacterial Vaginosis-Limitations and Need for Innovation J Infect Dis. 214(1):S14-S20. https://doi.org/10.1093/infdis/jiw159; PMid:27449869 PMCid:PMC4957510
Joana Castro, Daniela Machado, Nuno Cerca. 2019, May. Unveiling the role of Gardnerella vaginalis in polymicrobial Bacterial Vaginosis biofilms: the impact of other vaginal pathogens living as neighbors ISME J. 13(5):1306-1317. https://doi.org/10.1038/s41396-018-0337-0; PMid:30670827 PMCid:PMC6474217
Katherine Fethers, Jimmy Twin, Christopher K. 2012. Bacterial Vaginosis (BV) Candidate Bacteria: Associations with BV and Behavioural Practices in Sexually-Experienced and Inexperienced Women PLoS One. 7(2). https://doi.org/10.1371/journal.pone.0030633; PMid:22363457 PMCid:PMC3281856
Nagaraja P. 2008. Antibiotic resistance of Gardnerella vaginalis in recurrent bacterial vaginosis. Indian J Med Microbiol. 26(2):155-157. https://doi.org/10.4103/0255-0857.40531; PMid:18445953
De Backer E, Verhelst R, Verstraelen H et al. 2006. Antibiotic susceptibility of Atopobium vaginae. BMC Infect Dis. 6:51. https://doi.org/10.1186/1471-2334-6-51; PMid:16542416 PMCid:PMC1468414
Bradshaw CS, Morton AN, Hocking J, Garland SM, Morris MB et al. 2006. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J. Infect. Dis. 193:1478-1486. https://doi.org/10.1086/503780; PMid:16652274
Austin MN, Meyn LA, Hillier SL. 2006. Susceptibility of vaginal bacteria to metronidazole and tinidazole. Anaerobe. 12(5-6):227-230. https://doi.org/10.1016/j.anaerobe.2006.06.002; PMid:16893662
Nyirjesy Paul, Schwebke Jane R. 2018. Secnidazole: next-generation antimicrobial agent for bacterial vaginosis treatment. Future Microbiology. 13(5):507-524. https://doi.org/10.2217/fmb-2017-0270; PMid:29327947
Schwebke JR, Morgan FG Jr, Koltun W, Nyirjesy P. 2017, Dec. A phase-3, double-blind, placebo-controlled study of the effectiveness and safety of single oral doses of secnidazole 2 g for the treatment of women with bacterial vaginosis. Am J Obstet Gynecol. 217(6). https://doi.org/10.1016/j.ajog.2017.08.017; PMid:28867602
Faught BM, Reyes SJ. 2019, Sep. Characterization and Treatment of Recurrent Bacterial Vaginosis. Womens Health (Larchmt). 28(9):1218-1226. https://doi.org/10.1089/jwh.2018.7383; PMid:31403349
Gillis JC, Wiseman LR. 1996, Apr. Secnidazole. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic use in the management of protozoal infections and bacterial vaginosis. Drugs. 51(4):621-38. https://doi.org/10.2165/00003495-199651040-00007; PMid:8706597
Kriuchko TO, Poda OA, Nesina IM. 2019. Pidkhid do profilaktyky y likuvannia nealkoholnoi zhyrovoi khvoroby pechinky v ditei z ozhyrinniam iz pozytsii suchasnykh mizhnarodnykh rekomendatsii. Zdorove rebenka 14;2.
Silina NK, Koval HM, Silina TM, Berezhnoi VV. 2017. Mikrobiolohichni aspekty dysbiozu pry bezplidnosti i nevynoshuvanni vagitnosti ta ihnia korektsiia. Zdorove zhenshchynы 10(126):50-52. https://doi.org/10.15574/HW.2017.126.50
Gopchuk OM. 2016. Zastosuvannia polinenasychenyh zhyrnyh kyslot omeha-3 u kompleksnii terapii giperandrogennykh staniv. Medychni aspekty zdorovia zhinky 1.
##submission.downloads##
Опубліковано
Номер
Розділ
Ліцензія
Авторське право (c) 2020 Здоров’я жінки
Ця робота ліцензується відповідно до Creative Commons Attribution-NonCommercial 4.0 International License.
